Hematology is concerned with the study of blood diseases. This field includes molecular testing for leukemia – cancer of the blood and bone marrow – an abnormal proliferation of white (and other) blood cells.

Leukemia is divided in acute (A) and the more slowly growing chronic (C) disease. According to the kind of blood cells affected we know lymphocytic (L) and myelosgenous (M) leukemia, which are abbreviated ALL, CLL, AML and CML. Chromosomal aberrations, generating fusion transcripts of two non-related genes and therefore abnormal proteins are the most frequent cause for these leukemia. The fusion transcripts are unique in the patient and are detectable by RT-PCR. During the therapy, the amount of fusion transcript can be quantified, using a housekeeping gene as reference.

CML occurs mainly with adults and is caused by the translocation t(9;22), also known as Philadelphia chromosome. The fusion transcript is named bcr-abl. ALL is the most common leukemia in children and can have different causes, including translocation t(9;22). CLL affects adults over the age of 55 and is related to immunoglobulin rearrangements. AML is found in adults and children. One subtype of AML is acute promyelocytic leukemia (APL), characterized by the translocation t(15;17) with the fusion transcript PML-RAR. Other translocations which are related to AML are t(8;21), causing the fusion transcript AML-ETO, and inversion 16 (inv16), causing the CBF-MYH11 transcript.

We offer several kits for the detection of fusion transcripts and two different reference genes, G6PDH (Emig et al., 1999) or Abl1 (EU recommendation). All kits are single target and contain LC640 as the reporter dye (channel F2 / 640).





inv 16

JAK2 Mut Screening